Literature DB >> 28620841

Device-Based Approaches for the Treatment of Arterial Hypertension.

Jens Jordan1,2.   

Abstract

Device-based antihypertensive treatments have primarily been developed and clinically tested for patients with hypertension refractory to pharmacological treatment. Most but not all device-based treatments target the sympathetic nervous system and provided important new insight in the mechanisms of human hypertension. This review provides an overview on the scientific rational and clinical data on recent device-based antihypertensive treatment approaches. Device-based treatments targeting the sympathetic nervous system include catheter-based renal nerve ablation, electrical carotid sinus stimulation, modulation of baroreflex transduction through a dedicated carotid stent, carotid body denervation, and deep brain stimulation. Creation of a defined arteriovenous stent with a coupler device and removal of stimulatory antibodies against alpha adrenoreceptors have also been tested. The clinical evidence differs from therapy to therapy with the largest dataset for renal nerve ablation followed by electrical carotid sinus stimulation. Yet, none has been proven efficacious in sham-controlled clinical trials, and none has been shown to reduce cardiovascular morbidity or mortality. Before efficacy is proven, these treatments should not be part of routine medical care and only be applied in the setting of clinical studies.

Entities:  

Keywords:  Antihypertensive treatment; Carotid sinus stimulation; Device-based treatment; Hypertension; Renal denervation

Mesh:

Year:  2017        PMID: 28620841     DOI: 10.1007/s11906-017-0755-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  64 in total

1.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

2.  Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension.

Authors:  Manuel Wallbach; Luca-Yves Lehnig; Charlotte Schroer; Stephan Lüders; Enrico Böhning; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Hypertension       Date:  2016-02-22       Impact factor: 10.190

3.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

4.  Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension.

Authors:  M Wallbach; Luca-Yves Lehnig; Charlotte Schroer; Hans-Joachim Helms; Stephan Lüders; Daniel Patschan; Susann Patschan; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

Review 5.  The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature.

Authors:  John P Foran; Ajay K Jain; Ivan P Casserly; David E Kandzari; Krishna J Rocha-Singh; Adam Witkowski; Barry T Katzen; David Deaton; Peter Balmforth; Paul A Sobotka
Journal:  Catheter Cardiovasc Interv       Date:  2014-11-01       Impact factor: 2.692

6.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

Review 7.  Renal denervation for resistant hypertension.

Authors:  Giuseppe Coppolino; Anna Pisano; Laura Rivoli; Davide Bolignano
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

8.  Unloading arterial baroreceptors causes neurogenic hypertension.

Authors:  Terry N Thrasher
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-04       Impact factor: 3.619

9.  Deep brain stimulation can regulate arterial blood pressure in awake humans.

Authors:  Alexander L Green; Shouyan Wang; Sarah L F Owen; Kangning Xie; Xuguang Liu; David J Paterson; John F Stein; Peter G Bain; Tipu Z Aziz
Journal:  Neuroreport       Date:  2005-11-07       Impact factor: 1.837

10.  Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension.

Authors:  Katrin Wenzel; Hannelore Haase; Gerd Wallukat; Wolfgang Derer; Sabine Bartel; Volker Homuth; Florian Herse; Norbert Hubner; Herbert Schulz; Marion Janczikowski; Carsten Lindschau; Christoph Schroeder; Stefan Verlohren; Ingo Morano; Dominik N Muller; Friedrich C Luft; Rainer Dietz; Ralf Dechend; Peter Karczewski
Journal:  PLoS One       Date:  2008-11-17       Impact factor: 3.240

View more
  7 in total

1.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

2.  MiR-20b-5p contributes to the dysfunction of vascular smooth muscle cells by targeting MAGI3 in hypertension.

Authors:  Minzhi Xu; Ting Yu
Journal:  J Mol Histol       Date:  2022-01-05       Impact factor: 2.611

Review 3.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

Review 4.  Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.

Authors:  Gino Seravalle; Fosca Quarti-Trevano; Jennifer Vanoli; Chiara Lovati; Guido Grassi
Journal:  Clin Auton Res       Date:  2021-02-19       Impact factor: 4.435

5.  Laparoscopic based renal denervation in a canine neurogenic hypertension model.

Authors:  Chunlai Shao; Yan Zhou; Tao You; Boxin Xue; Pieter R Stella; Ting Bo Jiang; Zhigang Miao; Longjiang Xu; Longsheng Lan; Guang Rong
Journal:  BMC Cardiovasc Disord       Date:  2020-06-11       Impact factor: 2.298

6.  Precision Targeted Ablation of Fine Neurovascular Structures In Vivo Using Dual-mode Ultrasound Arrays.

Authors:  Rajagopal N Aravalli; Dusty Van Helden; Dalong Liu; Parker O'Brien; Hasan Aldiabat; Alexandru-Flaviu Tăbăran; M Gerard O'Sullivan; H Brent Clark; John W Osborn; Emad S Ebbini
Journal:  Sci Rep       Date:  2020-06-08       Impact factor: 4.379

Review 7.  Molecular Mechanisms of Kidney Injury and Repair in Arterial Hypertension.

Authors:  Laura Katharina Sievers; Kai-Uwe Eckardt
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.